MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/pai.12555

Медицинская библиотека · Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2016

Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.

Novák Zoltán, Yáñez Anahí, Kiss Ildikó, Kuna Piotr, Tortajada-Girbés Miguel, Valiente Román, “Bilastine Paediatric Safety Study Group”

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Regulations on medicinal products for paediatric use require that pharmacokinetics and safety be characterized specifically in the paediatric population. A previous study established that a 10-mg dose of bilastine in children aged 2 to <12 years provided an equivalent systemic exposure as 20 mg in adults. The current study assessed the safety and tolerability of bilastine 10 mg in children with allergic rhinoconjunctivitis and chronic urticaria.

METHODS

In this phase III, multicentre, double-blind study, children were randomized to once-daily treatment with bilastine 10-mg oral dispersible table (n = 260) or placebo (n = 249) for 12 weeks. Safety evaluations included treatment-emergent adverse events (TEAEs), laboratory tests, cardiac safety (ECG recordings) and somnolence/sedation using the Pediatric Sleep Questionnaire (PSQ).

RESULTS

The primary hypothesis of non-inferiority between bilastine 10 mg and placebo was demonstrated on the basis of a near-equivalent proportion of children in each treatment arm without TEAEs during 12 weeks' treatment (31.5 vs. 32.5%). No clinically relevant differences between bilastine 10 mg and placebo were observed from baseline to study end for TEAEs or related TEAEs, ECG parameters and PSQ scores. The majority of TEAEs were mild or moderate in intensity. TEAEs led to discontinuation of two patients treated with bilastine 10 mg and one patient treated with placebo.

CONCLUSIONS

Bilastine 10 mg had a safety and tolerability profile similar to that of placebo in children aged 2 to <12 years with allergic rhinoconjunctivitis or chronic urticaria.

Для цитирования: Novák Zoltán, Yáñez Anahí, Kiss Ildikó, Kuna Piotr, Tortajada-Girbés Miguel, Valiente Román, “Bilastine Paediatric Safety Study Group”. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2016. DOI: 10.1111/pai.12555.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.